Market Overview

UPDATE: Cantor Fitzgerald Lowers PT on Pernix Therapeutics Holdings on Declining Prescription Trends

Related PTX
Pernix Releases Positive in vitro Abuse Deterrent Data for Third Generation Extended Release Hydrocodone ZX007
Thursday's Hedge Fund Moves: A Look At Small & Micro-Caps

In a report published Tuesday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Sell rating on Pernix Therapeutics Holdings (NASDAQ: PTX), but lowered the price target from $2.50 to $2.00.

In the report, Cantor Fitzgerald noted, “We have watched Pernix's prescription trends decline over the third quarter (monthly Pernix/Cypress/Hawthorn TRxs for the July-Aug period are down 15.5% Y/Y; and Silenor TRxs declined 8.6% Y/Y; weekly September scripts show similar declines). We also confirmed with management that former CEO, Cooper Collins has recently taken charge of the sales force, which we believe is an organizational attempt to rectify the prescription decline trajectory (though management indicated otherwise). Management still points to expense reduction as a tool to restoring profitability, but that is a short-term lever without effective growth strategies, in our view. We reiterate our SELL rating and lower our PT from $2.50 to $2.00 due to increased commercial risk in the business as well as our view that sales will continue to decline (negative terminal value based on DCF analysis).”

Pernix Therapeutics Holdings closed on Monday at $2.72.

Latest Ratings for PTX

Jun 2015Brean CapitalInitiates Coverage onBuy
Apr 2015Piper JaffrayInitiates Coverage onOverweight
Mar 2015OppenheimerInitiates Coverage onOutperform

View More Analyst Ratings for PTX
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Irina RivkindAnalyst Color Price Target Analyst Ratings


Related Articles (PTX)

Get Benzinga's Newsletters